2 active not recruiting, 2 completed, 2 not yet recruiting, 2 recruiting. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Not yet recruiting 2, Unknown 2, Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Penile Squamous Cell Carcinoma: new trials by email Literature Review of Penile Squamous Cell Carcinoma trials Research Report on Penile Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer Sacituzumab Tirumotecan - Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Latin American Cooperative Oncology Group | 37 | 2027-01-01 | 2026-09-11 |
| Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma Amivantamab - Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Latin American Cooperative Oncology Group | 58 | 2026-11-01 | 2026-09-14 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas EVOLVE104 - Bladder Cancer, Squamous Cell Carcinoma of the Lung | Phase 1 | Recruiting | EvolveImmune United, Inc | 160 | 2025-11-13 | 2026-09-15 |
| Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Carboplatin/Paclitaxel, Pembrolizumab, Partial or total penectomy with inguinal and/or pelvic lymph node dissection - Urologic Neoplasms, Urogenital Neoplasms | Phase 2 | Recruiting | The Netherlands Cancer Institute | 27 | 2024-08-13 | 2025-12-08 |
| Molecular Characterization of Penile Cancers in Developing Countries Penile Squamous Cell Carcinoma | Completed | Latin American Cooperative Oncology Group | 24 | 2021-12-17 | 2023-10-05 | |
| Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) Cabozantinib - Penile Squamous Cell Carcinoma | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 37 | 2019-08-01 | 2021-02-25 |
| Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma Avelumab - Penile Cancer, Penile Neoplasms | Phase 2 | Unknown | Centre Hospitalier Universitaire de Besancon | 32 | 2019-03-12 | 2023-04-21 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Pembrolizumab - Penile Squamous Cell Carcinoma | Phase 2 | Terminated | University of Alabama at Birmingham | 6 | 2016-10-01 | 2022-06-21 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-10-15 |
| Oral Rigosertib for Squamous Cell Carcinoma rigosertib - Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma | Phase 2 | Completed | Traws Pharma, Inc. | 64 | 2013-03-01 | 2017-06-26 |
Penile Neoplasms (4) · Anus Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Urinary Bladder Neoplasms (2) · Urogenital Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Adrenocortical Carcinoma (1) · Bile Duct Neoplasms (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Endometrioid (1) · Carcinoma, Giant Cell (1) · Carcinoma, Renal Cell (1)
Neoplasms (7) · Neoplasms by Site (7) · Urogenital Diseases (6) · Genital Diseases (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Carcinoma (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Male Urogenital Diseases (4) · Penile Diseases (4) · Urogenital Neoplasms (4) · Digestive System Diseases (3)
CTLA-4 Antigen (2) · Ipilimumab (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Specimen Handling (2) · cabozantinib (2) · pembrolizumab (2) · Biopsy (1) · CP protocol (1) · ON 01910 (1) · amivantamab (1) · avelumab (1)
Latin American Cooperative Oncology Group (3) · National Cancer Institute (NCI) (2) · Centre Hospitalier Universitaire de Besancon (1) · EvolveImmune United, Inc (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · The Netherlands Cancer Institute (1) · Traws Pharma, Inc. (1) · University of Alabama at Birmingham (1)
United States (5) · Brazil (3) · Belgium (1) · France (1) · Guam (1) · Italy (1) · Netherlands (1)
Fernando Cotait Maluf (2) · Andrea B Apolo (1) · Daniele Raggi, MD (1) · Fernando Sabino (1) · Karine Martins da Trindade (1) · Lisle Nabell, MD (1) · Michael Kurman, MD (1) · Sandip P Patel (1)
PMID 31969335, PMID 32620211, PMID 32915679, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 35031545, PMID 38243705, PMID 38358334, PMID 38954785, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
2018 (1), U10CA180888 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1), ZIABC011078 (1)